FDA Commissioner Marty Makary said publishing complete response letters recognizes public interest in the transparency and credibility of agency decision-making about drugs. He also said the move complies with an executive order that covers the communication of scientific data. The post Embracing Transparency, FDA Will Make All Future Drug Rejection Letters Public appeared first on MedCity News.| MedCity News
Eschewing the traditional model of financing biotech startups milestone to milestone to support a lead asset, Treeline Biosciences’ well-funded pipeline is comprised of multiple complementary programs. Select investors have supported the approach of Treeline, which said it has raised more than $1.1 billion to date. The post Startup Treeline Bio Emerges From the Shadows With $1B+ Raised and 3 Cancer Drugs in the Clinic appeared first on MedCity News.| MedCity News
Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s room for many MASH drugs with the treatment landscape expected to shape up to include combinations of therapies bringing different approaches to this fatty liver disease.| MedCity News
As RNA biology and RNA therapeutics emerge in the mainstream of pharma, RNA foundation models offer massive potential for revolutionizing R&D.| MedCity News
Repare Therapeutics is cutting discovery and preclinical work to focus on its clinical-stage cancer drugs. The most advanced program is camonsertib, whose rights Repare recently regained from Roche after the pharma giant terminated an alliance started in 2022.| MedCity News
This responsibility goes beyond mere box-ticking; it requires a deep, introspective examination of our own biases and blind spots and a genuine commitment to putting the well-being of the communities we serve first.| MedCity News
To address the complicated healthcare landscape in the U.S., Pfizer launched a new direct-to-consumer virtual service called PfizerForAll. It follows Eli Lilly, which launched a similar product in January.| MedCity News
OMNY Health — a national data ecosystem that facilitates biotech and medical research — launched a data network consisting of EHR data from more than 645,000 GLP-1 users. The data network seeks to give OMNY’s life sciences and health system partners a vast source of GLP-1 data that is related to patient demographics and social determinants of health.| MedCity News
We can’t wait for others to find a solution to high drug prices. It’s clear what should happen in a functioning drug pricing market federally and in California, but it is not happening today.| MedCity News
NOWDiagnostics’ First To Know has FDA De Novo marketing authorization as a new test for syphilis. The at-home product needs only a single drop of blood to test for this sexually transmitted infection.| MedCity News
